If you’re a decision maker at your company, you need to be on the bleeding edge of, well, everything. But before you go signing up for seminars, conferences, lunch ‘n learns, and all that jazz, just know there’s a far better (and simpler) way: Subscribing to The Deep View.

This daily newsletter condenses everything you need to know about the latest and greatest AI developments into a 5-minute read. Squeeze it into your morning coffee break and before you know it, you’ll be an expert too.

Subscribe right here. It’s totally free, wildly informative, and trusted by 600,000+ readers at Google, Meta, Microsoft, and beyond.

The AI x bio field is moving incredibly fast. It’s getting hard to keep up. My free newsletter BAIO solves that problem for you. Twice a week I’ll tell you the what, the why and the how - and you’ll be up to speed in five minutes time. Simple as that.

On April 8, something unusual - and, frankly, overdue - will happen: longevity advocates will rally in cities across Europe to push the fight against aging into the public and political mainstream.

The demands are simple:

☑️ Major increases in funding for basic aging research.

☑️ Regulatory pathways for therapies that target aging.

The message is clear: aging should no longer be treated as a fixed background condition, but as something medicine and society should confront directly.

Confirmed cities include Amsterdam, Berlin, Brussels, London, Madrid, Paris, Rome, and Stockholm, with more possibly joining. The rallies will also be livestreamed, with expert speakers, hosted by Anastasiia Egorova.

I’ve played a small supporting role in this effort and will join the rally in Stockholm. If you want to take part you can sign up here.

It was the squarest of pegs, it was the roundest of holes. And it's not like we didn't know. We've known for years. We just kept assuming the fit would somehow happen - that the solution would materialize on its own, that the pieces would eventually snap into place.

The square peg: aging is malleable. We know more about the biology of aging than ever before. We have candidate drugs. We have animal data. We have plausible mechanisms. We can slow aging, and maybe, down the line, even reverse it.

The round hole: how do we prove any of that in humans? The system for testing it was never designed for this problem.

To be fair, there have been earlier attempts to address it. The TAME trial - Targeting Aging with Metformin - was the proposed trial trying to crack open the regulatory question of whether aging itself could serve as a clinical trial endpoint*. It never got off the ground because of a lack of funding.

* To be a little more precise: TAME was designed as a proof-of-concept geroscience trial to test whether metformin could delay the onset of a composite of major age-related diseases and functional decline. But potato, potahto.

Thankfully, and finally, the logjam is starting to break.